CVD, non-CVD mortality increases with outpatient use of Azit
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Outpatient azithromycin use is associated with an increased risk for cardiovascular and noncardiovascular mortality, according to a study published online in JAMA Network Open.

The relative and absolute risks of cardiovascular and sudden cardiac death were estimated after an outpatient azithromycin prescription compared with amoxicillin using data from two large, diverse, community-based integrated care delivery systems. Data were included for 7,824,681 antibiotic exposures among 2,929,008 unique individuals.

- The researchers found that azithromycin was associated with a significantly increased risk for cardiovascular death within five days of exposure, but not sudden cardiac death.
- At six to 10 days after exposure, there were no increases in risk observed.
- In patients within the top decile of cardiovascular risk, results were similar. Within five days of exposure, azithromycin also was associated with an increased risk for noncardiovascular death and all-cause mortality.

"Although these analyses cannot establish causality, prescribers should be aware of this potential association," the authors write.

Source: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767245
Dr. K●●●●●p S●●●h and 1 others like this
Like
Comment
Share